PTPN11 and leukemia: Notably, identified de novo mutations influenced the GEP for samples with mutations in the dominant leukemia clone, i.e., Kras and Ptpn11 (MAF 0.39–0.59), now clustering closely to those with a constitutively expressed mutation; this was not seen for mutations with MAF ≤ 0.30 (Fig. 4c).